BACK vs XTLB vs NRXP vs ATXI vs AEYE

For growth investors, AudioEye, Inc.

(AEYE) is the stronger pick with 14. 5% revenue growth year-over-year, versus -98. 6% for IMAC Holdings, Inc. (BACK). The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, AudioEye, Inc.

(AEYE) delivered a total return of -60. 2%, compared to -100. 0% for Avenue Therapeutics, Inc. (ATXI). Over 10 years, the gap is even starker: AEYE returned +102. 2% versus ATXI's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Avenue Therapeutics, Inc.

(ATXI) is the lower-risk stock at -0. 11β versus AudioEye, Inc. 's 2. 29β — meaning AEYE is approximately -2182% more volatile than ATXI relative to the S&P 500. On balance sheet safety, XTL Biopharmaceuticals Ltd. (XTLB) carries a lower debt/equity ratio of 3% versus 15% for AudioEye, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), AudioEye, Inc.

(AEYE) is pulling ahead at 14. 5% versus -98. 6% for IMAC Holdings, Inc. (BACK). On earnings-per-share growth, the picture is similar: Avenue Therapeutics, Inc. grew EPS 98. 8% year-over-year, compared to -5. 4% for IMAC Holdings, Inc.. Over a 3-year CAGR, AEYE leads at 10. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

AudioEye, Inc.

(AEYE) is the more profitable company, earning -7. 6% net margin versus -125. 5% for IMAC Holdings, Inc. — meaning it keeps -7. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AEYE leads at -7. 9% versus -78. 0% for BACK. At the gross margin level — before operating expenses — ATXI leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

In this comparison, BACK (100.

0% yield) pays a dividend. XTLB, NRXP, ATXI, AEYE do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, IMAC Holdings, Inc.

(BACK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 05), 100. 0% yield). NRx Pharmaceuticals, Inc. (NRXP) carries a higher beta of 1. 91 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (BACK: -100. 0%, NRXP: -96. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (BACK (Healthcare) and XTLB (Healthcare) and NRXP (Healthcare) and ATXI (Healthcare) and AEYE (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: BACK is a small-cap income-oriented stock; XTLB is a small-cap quality compounder stock; NRXP is a small-cap quality compounder stock; ATXI is a small-cap quality compounder stock; AEYE is a small-cap quality compounder stock. BACK pays a dividend while XTLB, NRXP, ATXI, AEYE do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.